Intellia Therapeutics (NTLA) 8 Aug 242024 Q2 Earnings call transcript

Good morning, and welcome to Intellia Therapeutics Second Quarter 2024 Financial Results Conference Call. My name is Drew, and I will be your conference operator today.[Operator Instructions]. This conference is being recorded at the company's request and will be available on the company's website following the end of the call. [Operator Instructions].

I will now turn the conference over to Ian Karp, Senior Vice President of Investor Relations and Corporate Communications at Intellia. proceed. Please

company's and Earnings Welcome Intellia discussion Call. press outlining operator, Second Intellia today's being be on broadcast issued morning, as archived a will and release live, the at release intelliatx.com. on XXXX can quarter Quarter Intellia's be Earlier website. the section and good of website This the you, topics This to call. Investor on everyone. Therapeutics a well Thank as this for found progress this Media call company's is morning, replay

and I'd call undertakes on to information risks to statements refer time, sec.gov this Intellia and uncertainties. to during this management like listeners All is law. call, as Intellia and for unless this you that our a At to no today, SEC duty information of take update minute the forward-looking ask presented remind of by filings a may available current discussion certain required make that potential at

Intellia room Scientific the Officer; of in Joining me Chief Walsh, Chief Laura the is in Dulac, Also Liron vivo are Officer; Executive from for Q&A Officer. Head Financial available Ed Sepp-Lorenzino, for and Development Chief Leonard, programs. John

and to Medical business highlights. will Lauren us Officer, Chief conferences. will pipeline and questions. the recent is with our clinical Ed progress call updates unable review we David open participating updates Lebwohl, will but begin Our provide he in will today, join financials be John for investor upcoming on before R&D our then

the Chief that, John, Officer. now our turn with to over I'll And call Executive

we're editing developing joining of all gene potentially curative us everyone, morning, Good harnessing and for you, Thank you thank CRISPR-based for today. power Intellia, the treatments. At Ian.

platform. the multiple our quarter continued with to of our and another XXX forefront report proud spectrum are over the of at programs undoubtedly full patients and and innovation substantial with Now across editing gene We're development, clinical we revolution. in pipeline therapies investigational dosed progress

condition with research of It Despite convenience. hereditary angioedema, and efficacy market are clear through known HAE also start episodes that as as that a heard treatments, existing for of seeking and swelling. I'll loud NTLA-XXXX recurrent the fatal and treatment physicians manifests is patients from our patients HAE. potentially improved we've and debilitating unpredictable and

tell what Beyond that it that, want challenges that live and treatments patients many from is life us their most free even to they chronic today. while the with available come on a disease

prophylactic attack emerging therapies with pursuing total is reduction While are treatment differentiate attempt therapy, what of in in improvements shift or modest other current intervals a paradigm dosing and rate themselves we for to extending HAE. the

treatment untethered reality. and NTLA-XXXX are of we treatment Our our a gene complete in believe response from both provide is a patients making a goal outcome it is and This technology, revolutionary patients and administration. single for are editing the of free a physicians seek is after the outcome that from we requirements to which with chronic attacks advancement

XX study in drug. reduction of to In following data XX all latest single Phase the June, for completely we X a the patients, in of observed And follow-up. attacks patients continue I NTLA-XXXX. be XX the administration positive reported from long-term XX% treated across we the attack-free to Of months a

all primary efficacy disease. to NTLA-XXXX in met results for be II were were NTLA-XXXX a of secondary announce life-threatening this the are onetime These we to the functional XX-week Importantly, primary its XX from Phase period in endpoints to thrilled observation care The infusion-related mostly unprecedented demonstrate events frequent of the at Today, study. most X. continue reinforce these adverse and data grade potential reactions the favorable profile. patients a which safety fatigue,

objective the therapy fourth XX-milligram level. in XX-week included safety, of reminder, to study at the period. further and the of The key efficacy results endpoint in Phase to the the placebo-controlled from III evaluate endpoints to efficacy quarter observation change of the XX-milligram acute month the the doses was attacks protein forward Phase the number Key of XX, angioedema trial. meeting per plan X angioedema during the angioedema the reduction pivotal the randomized, move to number to total attacks kallikrein safety this and medical weeks global II the was a detailed The month requiring primary a attacks which secondary month the ongoing number Phase of determine the As doses. primary of per baseline plasma in X a year. of was into We per during II and present

As disclosed in our we results line will what limiting of be discussion today's top to such, we release. press the

XX NTLA-XXXX attacks to dose observed. single in led No findings or XX-milligram deep A with patients HAE. new of for reductions were safety

higher of elimination the number achieve to Phase We which who and of into patients greater XX-milligram selected prior because advance have saw complete now Phase consistent to attacks the XX-milligram dose global cohort, results. kallikrein reduction I the dose is III a the we importantly, compared with trial

the we completed believe We with understanding a clear end recently and successful to of FDA. of positive we completed have have addition the a In meeting the path addressing their results, Phase II forward. questions

second to in vivo the for the will will of year be standard come NTLA-XXXX We III submit most to we NTLA-XXXX begin this to to HAE. first a strongly editing track XXXX. market. on gene it trial plan that And believe of anticipate and for reset the importantly, therapy Phase half care are positive the BLA the We in in

name, has competitor amyloidosis. long-standing hypothesis is for confirmed short. our Switching a clinically The Recent to now a treatment leads that nex-z important to TTR reduction of now clinical This patients patients. lead data the NTLA-XXXX for result or to ATTR that of new even improvement confidence in nex-z nexiguran ziclumeran the the drug meaningful and our for better with an in understanding increases further cardiomyopathy. field's advancement outcomes this disease, could

deep TTR and durable I consistently reductions the observed Phase on the based is belief in Our study.

well the is that trial recently clinical reported designed. competitor Further, data ongoing MAGNITUDE reaffirm

As appropriate, our will additional learnings incorporate into they become trial available. as we

The trial ahead projections. well rapid continues MAGNITUDE the enrollment to of of internal track our

we're physician over patient regulatory in in and interest well also the significant In dozen trial, the global addition XX to total, over are study. clearance actively enrolling with regulatory around sites and at a the received approvals for world. countries In now we've progressing the

Building on our we initiate on track significant to trial by are the polyneuropathy progress in for cardiomyopathy, pivotal year-end.

of placebo-controlled regions TTR As a expected limited ex-U.S. silencers. previously announced, trial be in to study XX conducted to patients the no is or access with small approximately

from TTR the and presenting Finally, plan of include reduction the XXXX. we to half to We and well as anticipate clinical and X-minute TTR build other these such endpoints, both as reported as data walk arms clinical CM recently from will PN look test in ongoing forward other in study data NT-proBNP, insights data Phase trials. mNIS+X. second silencer I the upon safety We

by and evolution than editing gene making be transforming our for commercial X insertion in with expected vivo our In to active of parallel a us Phase first closer trials late-stage development all from With pivotal and ever therapies. to gene investments organization. onetime our exciting strategic our study, to we're year-end, telling to III clinical clinical the future medicine execution,

and companies Directors; the appointment of development of the commercialization invaluable. commercial financial evolution. our coupled global this and recent and Treasurer. we Officer with as experience, be is Brian Chief biotech experience Brian's will of at by success Financial This Ed Board extensive to launches product its disease track rare chapter Dulac, in as exemplified deep clinical and stage Goff, Similarly, business our critical next will be leading enter record

Scientific Officer, our hand Chief the Laura, and over program NTLA-XXXX the who'll efforts. to call now R&D I'll on updates provide our

Italia, everyone. gene vivo the broadest in applications. morning, editing delivery Good of toolbox Thank you, and industry's we're technologies John. At therapeutic deploying vivo and for ex novel

begin with Let me NTLA-XXXX.

disease. week, antitrypsin the Medicine United we Regulatory products, to patients from approval received with last in regulatory associated Kingdom's the and deficiency initiate alpha-X announced we Healthcare first-in-human study Agency lung As

this Following program releasing the leading the IX second clearance therapy, platform the effect insertion factor enter of over IND permanently our engine. clinic, we from the program, accomplishment of modular research traditional without industry gene Unlike protein our approach waning set and gene our Regeneron will another effected expect restore to time. a leveraging marks

precisely fully and restore to As insert a the permanently NTLA-XXXX wild-type of protein. production is designed alpha-X to reminder, secretion functional SERPINAX gene

to is patients demonstrated dose. to we alpha-X nonhuman single in to after what restore levels primates goal a normal replicate Our

LNP the The I Patients a to dose Phase dose Phase I/II tolerability, which study PK a to multicenter evaluate X from from PD we escalation the receive of NTLA-XXXX will AAV cohort template LNP. NTLA-XXXX, LNP to open-label a only a will in safety, enrolled. sequential variable and XX AAV delivers of of cohorts. of single The dose component with our the will design The NTLA-XXXX, Based up of delivers to single of DNA on be SERPINAX up NTLA-XXXX, study and learnings dose a X evaluating and dose be be XX X-part the milligrams. consists will a a will infusion CRISPR machinery. be cohort patients will AAV. and ascending be

will with first level of AAV expect that of in begin show cohort. we even some will the We activity doses

plan into of to dose the will the expansion single be further identified we've Once cohort a characterize Phase to optimal NTLA-XXXX. dose, activity move we the which II,

We are track second of to half first on the dose patient in year. the this

our whole could insertion we redefine in NTLA-XXXX of success, a with category and unlock pursue alpha-X gene new treated is diseases Assuming platform. how can vivo

tolerated. NTLA-XXXX an those were LNP-based Intellia's another landmark in our June, pharmacodynamic single was demonstrating milestone dose. In We redosing utilizing additive the gene well after field redosing vivo safety generally CRISPR with with consistent the yet when development of the editing. delivery exciting that another for pharmacodynamics ever platform, to Typically, and effect. with the achieved platform. presented with Intellia Turning follow-on clinical data observed first enable dose of Overall,

is both patients developing proprietary The ability and a redose to LNP safety our successfully to in formulation our ensure to standard testament activity. these high

can with option platform look the Going push for year. for R&D as our be outside important boundaries of we we the could forward, CRISPR-based we We on more where to across expand our to technology. continue advantage clinical to broadly forward programs, Intellia this can while redose our progress do not the and liver updating go what planned an current you

quarter I'll provide hand over the results Financial will an to second financial our Officer, now of Chief XXXX. who our as on call update Ed,

Good maintain on Thank balance to and that continues Intellia platform. pipeline morning, everyone. strong allows to us you, execute sheet our a Laura.

plans. securities by XX, of marketable operations June and fund as $XXX.X cash equivalents XXXX. The $XXX.X part compared million stock proceeds company's of in from with million. by decrease Regeneron, collaboration April million was offset from million of At $X.X the used related cash onetime million a was as December income technology XXXX, $XX.X of billion XX, company's $XX.X approximately payment were the of including to the million of decrease in $XX and proceeds Market $XX.X approximately cash, reimbursement $X to employee-based net million equity in collaborator received The Our program, driven to interest

million collaboration second was million second million $XX.X the revenue compared XXXX. the $X.X collaboration mainly was in the of $X quarter and AvenCell driven of a during quarter by to license related The Our decrease reduction revenue XXXX, agreement. to during

the was during during XXXX, $XX.X second $XXX.X were of XXXX. expenses stock-based the The primarily quarter million $XX.X million million compensation expenses. was $XX.X quarter a compensation. million XXXX, quarter quarter quarter second Stock-based for by second R&D million decrease included to increase expense of compared the of expense for were to was G&A Stock-based of $XX.X quarter R&D million during of million second driven during $XXX.X the second to primarily the employee-related expenses of compensation decrease $X.X related XXXX. including in was million XXXX XXXX. compared a second G&A the in $X.X

to plans Finally, our balance operating we fund into late expect cash our XXXX.

to for To in questions. With be on continues looking caller. one editing, gene as now of many promise to questions do able best per will clinical all we Ed. to we'll Thanks, the to Intellia second of deliver conclusion, that, this are possible our address forward milestones and half the as important question we In several only year. take your

now may for Q&A. open the you Operator, call

Instructions]. [Operator

from with Morgan Stanley. Terence comes question first The Flynn

This for the is on on and congratulations progress. Chris Terence

you can is talk drug? the how against competitive HAE it Regarding about data, II Phase Ionis

Thanks, Chris.

for what take for. understanding the comments, the said regimen having XXXX. about we're patients therapy. improvements patients. that looking current the excited They're with looking be we deep primarily they're as therapeutic we're minor prophylactic starts way earlier to of disease very is And is a in And The trying available means are looking our to intervals. possible. approaching we're to that's as not and for what They're that not in As profile for any reset extensions looking medicines. dosing to actually not What is having normal

So we're that look we've elimination that That early longer no medication I to program at a available for we're in is patients dose that, of yourself responses for attacks Phase ability profile take the That's see to and any for. and looking as think to new think entirely A program, with leads category equal. shooting we without the be HAE and profile. of complete the as Phase in will profile information for. a all. our its development, we is our able seen of to at what resetting achieve drug be becomes the an that for and in II you'll We bar patients terms we're single

Kate Bank of next Mary with The question America. comes Davis from

need unmet owned the here, program program comment could AATD insertional the be the at Looking space? you market, the impactful how an wholly for current could in given on

as almost is deficiency complete exist of absence they our therapies currently a effective of Well, therapy. alpha-X it's assessment that antitrypsin

essentially of doesn't do. -- the that resetting is bar. what terms protein to view yet activity alpha-X We're our has antitrypsin have normal today. alpha sorry, that in Remember So fully open a protein wild-type that trying that trying production normal to of wide antitrypsin is deficiency the the we're exist it's

be with we as we're clinical market that XXXX. and excited one a program that the can one -- beginning in, about is large view very very so And very successful we this very,

The question comes Ha Dae with Gon next from Stifel.

Laura. I'll question a stick with Maybe also AAT. for

dose? AAT lung whether lingering about sort the As wild-type production, experience guess, deviations what Astellas, XXXX, pro-inflammatory on are the your behind also have specifically, we gets specifically the when from to the of effects what think I and the Audentes pathology. learnings still you might into can factored and AAV it your speak about And that to Z component, you are AAVX comes talk on biology some or AAT can your how AAT Z the having

do to and you with want that differences? Laura, some of So take start the dosing

Yes.

the for you thank question. Gon, Dae So

deliver to So insertion. using we're the here for AAV the template

with it's we're need a different when long cells of using you to that effect. to traditional ensure episomes So therapy approach quite where the have gene you duration load

including Audentes our not to have are AAVX. So much only lower, given diseases used used for what much, others doses but has that, liver-directed what using

that thing believe the the to a we have template insertion in hepatocytes again, to drive percentage going be fully levels So are few going of have need enough of to alpha-X is that's we to therapeutic.

have and not who minority Based have alpha-X disease, of on the liver our deficiency right? the That's data patients antitrypsin all patients.

type issue don't add? So anything in John, have we like expect to would any by having expressing patients you wild protein the it. who

I think speaks you, Thank that it. Laura.

The with Cowen. comes from Joseph next TD question Thome

quickly XXXX one the PN proposed on Maybe study.

patients be like this that? prior any to ex-U.S. in would would do But sense you of do the indicated anything an Or think open-label to an extension makes program think ex-U.S., approval entire think you for you sufficient? see setting? dosing you obviously do like that FDA the Would silencers. given or which patients I it availability would like of U.S. the be

question, extensively reviewed the with they're have what this Thanks we a FDA, Joe. looking We've and understanding for. for the

are agreements enrolling we're study conducting that States. They're We many going United alignment come be not cardiomyopathy in to indication where we requiring United that patients from outside study and inside the States. particular already on States. patients see the patients have our other United the how Remember that in to will they're dosed the

extensive prior to exposure So we'll see a very drug. the

comes The RBC. with Luca next from question Issi

a up to pipe, Great. Obviously, see for more approach. toward think why innovations time data Wondering But RNA evolve, the it. your Any for the approach Vertex of versus and the we kind approach better. think ADAR you if end down competitive on continues including, we're on are the coming their progress. I obviously, the can your editing of Much thoughts and just year. that clinical Maybe, other Congrats going contrast of the on one here and seeing first lot you is appreciate landscape approach there? compare Laura, to giving alpha-X.

right, in that of done, and to mechanism of right? action, primates, that's levels. the question. nonhuman can single one normal will humans, the in And the based Thank to potentially looking that the that you just we And XXXX, solution is but the have this ability that data demonstrated micromolar, dose. be the full that because with we translate going be if on in we going for think we have right, preclinical are differentiated. not So normal Look, achieve you right, believe I a seen, for to achieve

At day, of clinic. Of be the are the will pooling course, of there proof modalities end is in that the advanced. being the other the

I'll await data. So the clinical

comes from question next with The Barclays. Wang Gena

one of be medical the for hold in data, HAE is the Phase program. a the I also HAE HAE I II conference, good venue you presenting and for women partial the the of assume the regarding data. status ask the for full ACAAI Boston age question in What will full a is will reproductive at is clinical

Thanks, Gena.

position we As done, we're will, we're in through is what think look soon as where of go to share we data. you a very to in we and that forward the seeing always the we've as we exciting audience do as course, presenting data,

we've of women no was the not that's up partial thing. to the clinical childbearing as issues with respect clear one FDA. hold, I want addressed But correct. There the all to we potential, said, of just With

to study, up the the United until States. doing the childbearing have complete we've III potential, United and alignment around only been with but We of now States, of not be in women will the we respect exception Phase with the including as world,

the in full we and much that beginning very look population. results So forward trial collecting to

of of to of different of include and trial a patients would set childbearing degrees when with very that the done. the illness the to to begin is have expansive be just expansive goal I so limit can we add with potential, largest we're very label beyond that

next Jefferies. question Maury The with comes Raycroft from

Congrats say if Phase I'm say wondering on on there's the design. you effect feedback more or big wondering I'm to expectations? and in about can And more thoughts how trial's pivotal the there's II meeting would you and the anything be response study on update. the size placebo could latest your HAE particular, in if this from need

seen manufacturing I Maury. shared only successful. II would as preclinical the guess Phase presented, not We but I and approach I they've FDA Phase they've as our data seen data. clinical profoundly the Thanks, from program. earlier the meeting We've characterize the

than fundamental on the expose to interval there that take from done as variety Gena, Phase response profile III. a rate that over is XX per be of the The of key we that that. measured and We'll the to reduction, but the of know think decision weeks trial and will only drug, outcomes, opposed here, be will achieve the the so course, look We I as of complete expect very placebo-controlled size as these X-month We've patients. full will the people the of Phase question in about the was attack prior drug. excited very, to It II. who Phase patients will standard. a decide XX be different number for a shared we've And not things we to dose XX-milligram which we trial, and be we to that. into with this as done we're of that the dose that the And the population disease so now fewer will

believe advancing because to year. excited very will it vivo first approved of we're about before on Again, the the make any the track we're to very, for very program. begin the we just point, and CRISPR program be in this agent this end

with comes Leerink. The Foroohar question next from Mani

least functional than chronic know if take realistically a phrase study. for program we're the which a cetera, et have meant number not use off been to is majority talking commercialization study, HAE, from patients to is competitor path to some, for therapy The When cure functional about curative the others onetime Ionis, functional think to you're at of for the to the going what's SWITCH patients. you they therapy. curative studies, pursuing I more if what not of has reticent be SWITCH do have event you cure, a they with a like all which for therapy, about chose

your therapy? et terms your current of How keeping as do strategy data to therapy be on prophylactic can to patients physicians how on cetera. you there others off produced of a -- providing eventually do for nothing of larger you of there moving patients a think of to therapy polypharmacy of more it? Will patients of discontinuing for move patients providing broadly, of sets on the off be other by switch, you studies how couple on-demand take about input practice inform the think other of of data in to will therapy them, couple and operational advantage roll Or top off physicians part

know what can have to speak been on but give I may and getting if to Mani, X let That some don't perspective at. questions, I of try I me think them, you're all

words that First these patients. being very of for with judicious the use all, to the describe outcomes we we're

You, cure, determined that we to the Administration, the from a no but with a able single it a Again, these calling take for something decide is will drug, and goal speak achieving the itself. point application you therapy, yourself, to following Drug that's functional we What want Food have we'll the with longer as we're what remains regulatory and say you can of that. that, work be to view, evidence patients patients. of think to be call are

not mechanism want moving well With expect patients form. therapy whatever respect the who and us out patients work the we'll marketplace, that set tell have of switch. as look our we -- plays is to to immediately patients responding have and something very access the with that patients they be opinion incomplete of with the that that that having forward set them. by are with and who learn the us we a to existing will leaders these are drug, available propensity Doctors there's key a into of there to them. investigators to much forward a Then the are tell to which who agent have And drug that look to responses

We and in community as leaders with you be to Either But the get information in to a back not our position forward drug is may more profile the laid larger the do in we out. complete as we'll that's work field, switch currently be a study thinking we given and about a in way, way that talk get the there. believe unmatched. extremely successful will the marketplace we that

The next Lee Truist question Joon comes from with Securities.

on Mahdi is on progress. This the for Joon. Congrats

given now has a on reduction NTLA-XXXX, and XX% XX% PDUFA XX November CVS date So with showed Acoramidis survival. of

what So you of what bar regard? the to III you is MAGNITUDE XXXX think outcome do this expect study? Phase do now in be the for Basically,

the by that's are multiple put agents, in competitive silencer. have profile the have able based been or any results to reported which that reported a be and other whether forums, forward the that presented most Well, meet been stabilizer on prolonged expect we that a of any deepest achieve that been TTR we'll the we or

We are designed And or that Phase patient we to will think therapy been other that demonstrate stability to any we XXXX whether outcomes from on patients designed have of with have range of with what's and at the degrees that agents. their III population to on that cardiomyopathy. reported looked monotherapy is superior trial a that, different of existing a

stay tuned. So

well comments the the rate. now there's and into around our enthusiasm own a above with in lot world coming in said essentially our earlier, study patients marketplace very, the approval expected investigators As very of we quickly,

information So it be we're much as sure excited. I'm we'll we get road, down watched. will the share that And it, obviously, and

as as So we'll can. quickly proceed we

Markets. from comes BMO question Costas next Biliouris Capital The with

[ Costas. is This ] Dale for

from question one us. Just

program, NTLA-XXXX companies that the United think patient how on also recruiting other the you do given enrollment, competition for in the and Kingdom? So also about Beam editing

will that investigators We where other countries setting, the only we're but a confident and know in in U.K. sites, question. I we Phase patients have, they the the situation. Ireland certainly not we'll position look and work the for New see Zealand including Thanks be with the a have study us We quite in tell recruit results drug performing. competitive expeditiously a that for to being don't is how that this the and who

The with next question comes Cantor from Rick Fitzgerald. Bienkowski

on Congrats HAE. update in the

So number a Phase suppression of observations one then breakthrough there period I during of and the was from primary small attacks observation afterwards. data the of the was attacks complete

this presentation And full year, we will that's data to a And than just period? if the these for any patients date. primary present at for longer could patients are for So the follow follow-up see Phase later term? any later longer those observation II maybe you plans discuss a there

couple in study study, are through there's XX-week was a the in data observation. what case present the II patients that the In placebo a We'll but the of the Remember doses, X switch. Phase a II arm all I. as of differences Phase the from different Phase there And well. offered we

over to position placebo a in look be at to patients going time. ongoing not we're So

we've down of the every patients the follow we've one dosed I we'll present that the patients that expect every will thus these follow-up we've of the done treated information at single We irrespective of would single all of one as program. far. the with on road And appropriate patients times, that

Jay from Oppenheimer. comes question Olson next with The

Congrats on all the progress.

number be the when you'll are study sites you then about And of to For XXXX, for wrapping what could they're ESC? competing that up? you magnitude impacted can trials other looking talk in results HELIOS-B reported plan activate by the be study. the how for And that

different -- the countries Thank participating. world around of around variety spread a or companies anticipate for so sites the question. Sure. with XXX you We

said now XX of begin XXX-plus number the that increase that in About a enrolling about comments, As dozen we overall will in and active. far have the our so approval coming to there's given regulatory the sites weeks. are

enrollment already. so actually accelerating even strong beyond And to a we see expect start

a thought of we where cognizant how carry put different which few the over the accumulated the world, the very surmised. sites we about with as experience we doing don't far, we were see what months, we study around were yet. together work competitive really and and the As one countries was about to And thoughtful the in study, and last on we going that participate thus out and the which from that were situation to we're

of continue to to -- In time expectations, ahead be expect as continue said, I fact, that we and goes we're our we on. case the as

question next from Brian with Cheng The comes JPMorgan.

the redosing AATD? in didn't plan is patients for threshold redosing polyneuropathy of set your next a to build In it those reported Just or reduction studies perhaps achieve back of certain TTR happens? data, that any HAE if on there for the biomarker recently

for question, Thanks Brian. the

patients has remarkable I that sometimes far. level One not of lost that therapeutic, pharmacodynamic things single and outcome all doses to for, patient treated think exception, reductions we particularly those almost without when treated at of we've of which a is that across that been look that the really only the outcome. have other the Certainly, every is deem be that with achieved thus variability looking noteworthy is the that I see think you that outcome we're drugs the you the is pharmacokinetic of

walk doing. of And but we're will that of to doesn't the one to where about instances think a to is every editing program be that or than program. I quite that shooting the effect. It you The HAE, apply to case. it but we're purposes, think don't want doesn't is and situations, the I in apply amyloidosis the be may patients particular in mean, we seeing there the any where up can think one a all may would might for, be for doesn't think level way is of that the liver what the studies currently participating practical if case, we're lower unique. certain what here outside apply, to done I we kallikrein ongoing redosing program And instances

The Please ahead. with Seedhouse next go from comes Raymond Steve question James.

Timur Ivannikov This for Steve. is

it's improvements difficult pulmonary For been historically, disease, AATD exacerbations. FEVX lung and show to in

So do the will improvements neutrophil FDA you in think those showing points just reduction activity? showing elastase end the on besides require

think in that the of as experts It's requirements function or those approach may degree normal achieved. complete actually in we in space, abnormal of and well is that's evolving of a be different to patient. talking far a that than that complete in want the they to patients protein, never an do functional going can if cases, to achieved in the program. we we a those normalization less you're to as either to objective can information why first that patients. this as place, is expect to the for That's determine our from the normality we interactions, response normalize We indicate of for as need instances put the which than is because of that's aspects had protein the effect supplementary FDA as beneficial an the a space. them disease less And the the If as in is the levels best likely achieve position is

Tuerkcan comes next with The from JMP. question Silvan Citizens

Congrats on the data update.

period? observation the Phase post attacks long-term but HAE, I on about patients trial, the it, in of the know the don't can attack do I if still open-label most Just have with rate the no presentation, X you post recent XX comment you out

Thank you updates come. for for say I watch question, as the would they Silvan.

one the it. information, to share earlier said we'll all as patients. the of questions, we we these we'll And collect follow As of

very, excited We be dose XXXX. patients performing about very after these what we continue see to of how single their are and

with comes Bernstein. question William from next Pickering The

the all progress. on Congrats

not Now enroll? looks before a just your drop-in completes. are your trial rate, be likely to will silencer silencer assumptions can there to on that a patients and that would you potentially it speak on available become And who confirm during a already that MAGNITUDE you enrollment is eligible even cap? increasingly silencer Can

We very confirming and evolves, available think we study what in own silencers. becomes if it on HELIOS-B, available patients we'll terms as And in assumptions will interested drop-ins all, the data we're that design our address look trial. at may of that study the for some any have we appropriate from of our becomes as the at for of which be

available stay But now, those we've made it and for are which So as integral well provisions use, drugs as the stands study as tuned. not is tafamidis monotherapy. to

it will as adapt necessary. And story the changes, will as evolve. we So

The comes Goldman with next question Salveen from Sachs. Richter

is Lydia for on Salveen. This

with enrollment MAGNITUDE for Just progression regard on cardiomyopathy, to ATTR a the from quick one just us trial. the

an here last to enrollment? said that expect then just enrolled. were complete and provide you when think I there quarter, Could you you updated XX patients that figures

which, start ahead. very to lie continue be Again, in that we expectations. study, won't above our countries began the XX sites shared reported weeks doing to than more was the be the as the enrollment, a quarterly information that expand because strong that question. you We in XX Thank continues said, people basis. for after we and updates is running the we I we we had to giving have time it What up and wanted on see will in first

a rate encourage complete done terms we've proxies improve look overall think, that is study enrollment, the of to be, that. look of the would at work our place But enrollment. of of HELIOS would In objective in I you upon the for course, and I to to terms good

comes with Blair. next Myles The question William from Minter

micromolar. on there's question that mg of alpha-X, I think, going on your be And just just will initial is wide AAT Just curious are your to risk And a dose with? XX XX what reduction. because the you're normal definition if range range, XX achievable of final albumin with levels that

the locus going uncertainty with to the that's into not? that fact material albumin or if Just and be you're

We'll of the Laura, said just referred in you for you one shooting dose. to to terms turn who to what thing But we're speak XX-milligram albumin. can

I examples. holding will dose, at recent which, the We Maybe at therapy, to. in varying you LNP least what's study Laura, that is Phase gene in dose AAV again, speak for typical in levels constant below significantly be can the are our

Right.

this achieve, they from case, XXs. you what normal to XX. XX want that's the So we And right? right, vary right? in quoted goal right, we were in is levels, And to So that the

expect achieve what we're to able humans. that's we going to in be So

evaluated obviously in do see studies. With in way externally that patients albumin expression was decrease any our in And danger. GLP a regards we albumin toxicology to in not that could put

that, first the that have going And safety we're to the relevant. we be XXXX the first will to levels believe pristine. even we then we be alpha-X even will therapeutically designed for approach So dose, to the investigating doses to dose led again, the expect that of the trial that we expect

from The Liisa next with question Bayko ISI. Evercore comes

the This is Congrats on Jamie for ] progress. Liisa. [ on

III the composite endpoint, or do analysis So we stain method MAGNITUDE for like of Andersen-Gill like study. use Phase something you question plan ] HELIOS-B? What a for [ just have to single

ahead, But lie and that we details at disclose appropriate are those we'll interest. the time. appreciate question, your The

Ry The Forseth next question Guggenheim. comes with from

contemporary This that inter what's you've is research Ry from Debjit and notable or uptake team your across any PN ATTR seen? editing. internal to Is indication for switch suggesting there differences market for gene enthusiasm CM, HAE,

case us hereditary different our polyneuropathy, those is and can nature market are angioedema, Those otherwise every be event. to research tells episode is as the life we HAE want normal, and and said diseases, are cardiomyopathy comments, one of a most are their very want in and cardiomyopathy in episodic diseases, day progressive any they What normal. much that between cases, HAE in to patients as be with as possible. earlier that, attacks, of in have in They all fatal

market that very drug, ranging our disease to who the patients for taking the lives, HAE. patients XXXX research us live from how which attractive of patients suffering their they improve the be want So to have very, what controlled most who of fully patients preponderance to is will is tells

or in progressive disease, and perhaps of us is actually In have amyloidosis, succumbing many of several that patients we to their stopping these only progression will worse to the the disease. diseases with believe ultimately here instances, are cardiomyopathy, and getting the reversal. of but polyneuropathy not demonstrate cases some for worse The whether degree objective case the of

on, year years, results patients look of think we'll of followed couple ahead. would at be As you and Phase the we goes that lies a encourage that been have to be presenting the what in may now for indicative I I which

they whatever goal for need. it's meet that to want and from the patients end, the in our Intellia So suffer at best drugs disease available

question comes with Citi. from next Lebowitz David The

understanding Certainly, and on at guess, further What potential you adaptations. MAGNITUDE HELIOS-B you're design items anything interesting MAGNITUDE speak aspects trial that things specific what readout you I with most trial? and you of But that detailed indicate inform upcoming to of how, the to could might the directly can't the in ESC? focusing are the

about slower interest rate great Sure, interest more with some their and in particular learning patient severe us. that That's and in populations. how I level think event disease, details are of are interested many in disease a overall of an taking plays and reduction initial of and relationship between more in is out in in how patients general stage great plays us field a the events think, patients early we will a and the disease very rates be the What's important David. out we who of place It's be function question. And to of the to that TTR what others, have exciting will results.

constructed higher and when patients that other been we with Remember of that excluded levels as included of the who have many have heart Class allowing we baseline III our disease. patients studies requiring allowing done. trial, been well at as in in fact We're pro-BNP

in of tafamidis very the effect Remember as that the we and nature can up we're we a understanding on position come in to on be proceeds. will receiving need designed And drug that think what based the extent we with in our to we consider of we because that a interested something patients in study enrollment space. top with here, own We we're adapt it. we way be and the that strong it in in adapt the that early we think the will it learned, study will be what strongest really

from Our last Wolfe Chen Andy will question Research. with come

don't Brendan a or to still patients. up for treatments of and those although somewhat the Based activating signed saturated, prophylactic is patients on be chunk who is not Andy. Congrats for the This HAE on Phase move Phase to market your on II seem competitors III. have our understanding, success

treatment? So prophylactic expand are competing competitors right all Do your you for think the gene-editing the of could same pie now.

would therapy word, again, does that multiple presence look with the of terms of interviews. careful In ideal. a mean extensive yes. the The that we means. leading with think is our patient not space, be And and I discussions as this I investigators in involves respect saturation, to to market research, in how And therapy what

to having of that to patients means market want think never that most we'll meet normalize take of our normal. saturate them referred that this be to able to with disease. those that any we patients, It And the currently that ask is vast of be you and you to. preponderance need the drugs objective If

This like closing the for back Ian to over our concludes to question-and-answer I conference remarks. Karp any session. would turn

Thanks this and in discipline for Drew, while because it's like I I'd everyone's for give that and us -- in your we've through asking one the may for interest you, everyone's question gotten joining a to everyone, questions. Great. also thanks in Intellia. be time so much, a think thank special continued first today

summer. with to we continued continues. year great And rest everyone that, look the a of the forward we as wish updates So

The ended. conference has

You disconnect your may you. line. Thank now